Barry Bunin's Email & Phone Number

💼 Past Experience

Barry Bunin's CDD experiences: Collaborative Drug Discovery - CDDVAULT, CEO & PresidentBarry Bunin is currently a Entrepreneur In Residence at Eli Lilly from December 2003 to September 2004 (10 months). I have now taken on an EIR position at Eli Lilly where we are not only looking for good investments (of course) but also looking for disruptive business models for drug discovery. Basically I get paid to do what I'd be doing anyways, but with people I like and deep pockets behind the ideas. President & CSO at Libraria from February 2000 to October 2003 (3 years 9 months). Founder of Libraria (now Eidogen-Sertanty). Senior Scientist at Axys Pharmaceuticals from October 1996 to February 2000 (3 years 5 months). Medicinal Chemistry and Synthesis Services for Big Pharma Customers for HTS and Protease Inhibition (Axys Pharmaceuticals is now Celera). CEO & President at Collaborative Drug Discovery (CDD, Inc.), see: www.collaborativedrug.com in Burlingame, California. Collaborative Drug Discovery (CDD, Inc.) is a successful company working with thousands of leading distributed researchers - with a preference for working on neglected diseases. CDD provides quality chemical registration, SAR, and unique collaborative technologies for budget sensitive laboratories that also scale for complex collaborations (the CDD Vault).Here are some interesting CDD highlights:2019: CDD Vault celebrates 1,000,000th paying customer login2018: CDD Vault becomes leading whole solution for drug discovery informatics ( Activity & Registration, Inventory, Visualization, plus a highly differentiated, fast-saving ELN) 2017: CDD launches patented, new BioAssay Express (BAE) platform for “Assay Informatics” 2016: CDD Vault adds Inventory2015: CDD Vault Addsadvanced calculations, modeling, & visualization capabilities2014: CDD Celebrates 10 Year Users Meeting Together with Leading Scientists 2014: CDD Vault hosts >23 Million Compounds 2013: CDD Vault securely hosted >9 years – with 99.98% up-time2013: CDD passes >100,000 logins2012: CDD Launches GrantStorming Program 2012: CDD FISMA compliant and accredited 2012: NIH picks CDD for Neuroscience Blueprint Network2012: CDD celebrates 8 years in the cloud2011: CDD wins Bio-IT World Editors’ Choice Best Practices Award 2011: CDD celebrates 7 years hosting data securely in the cloud2011: MM4TB 5 year EU funded project with AstraZeneca, Sanofi-Aventis2010: GSK, Novartis, Pfizer, and NIH Collaborations Announced 2009: CDD surpasses >1 Million Compounds in the cloud 2008: Gates Foundation initial 2 year TB grant (ongoing and now extended >10 years) 2005:

🎓 Education

Barry Bunin's current education and work readiness:Barry Bunin is a Ph.D. candidate in Bioorganic Chemistry at UC Berkeley. Bunin has a background in chemistry from Stroudsburg University in Pennsylvania. Bunin completed his undergraduate studies at Columbia University in 1987. Bunin's current education and work readiness lies in his current position as an advisor to UC Berkeley students in Bioorganic Chemistry.Barry Bunin's work background and education prepared him for his current position as an advisor to UC Berkeley students in Bioorganic Chemistry. Bunin has a background in organic chemistry from a university with a strong organic chemistry program. His research experience inorganic chemistry has given Bunin the ability to provide sound advice to students when it comes to organic chemistry. Bunin's education and work readiness has prepared him to provide sound advice to students in his role as an advisor to UC Berkeley students in Bioorganic Chemistry.

💡 Technical & Interpersonal Skills

Barry Bunin has over 10 years of experience in the Pharmaceutical and Genetic Sciences with a preference in working on neglected diseases. Bunin is currently the President & Chief Scientist at Collaborative Drug Discovery, Inc., a successful company working with thousands of leading distributed researchers. Bunin provides quality chemical registration, SAR, and unique collaborative technologies for budget sensitive laboratories that also scale for complex collaborations. CDD has been awarded NIH funding for their project, MM4TB, which is focused on developing a single platform for assay informatics. Bunin also has experience with GSK, Novartis, Pfizer, and the NIH. Bunin’s goals at CDD are to provide high quality products to their customers, expand their customer base, and develop innovative products. Bunin is also highly experienced withiantialysis and echo-deep sequencing, which he has leverage over in his current role at CDD.